Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
379 participants
OBSERVATIONAL
2022-09-05
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Immune Response of COVID-19 Vaccination in Patients With Chronic Liver Diseases
NCT05007665
COVID-19 Vaccines in Patients With Chronic Liver Disease
NCT05017805
Antibody Response to COVID-19 Vaccines in Liver Disease Patients
NCT04775069
A Study to Evaluate Vaccines Against COVID-19 in the Real World
NCT04775056
Quantification of Binding and Neutralizing Antibody Levels in COVID-19 Vaccinated Health Care Workers Over 1 Year
NCT04910971
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
COVID-19 Vaccination Group
Subjects who have received at lease one dose of approved COVID-19 vaccine
Approved COVID-19 vaccine
Vaccination for COVI9-19
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Approved COVID-19 vaccine
Vaccination for COVI9-19
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Volunteer to participate in this study.
Exclusion Criteria
5 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tokyo University
OTHER
Nihon University School of Medicine
UNKNOWN
Humanity & Health Medical Group Limited
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
George Lau, MD
Role: PRINCIPAL_INVESTIGATOR
Humanity & Health Medical Group
Masao Omata, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Tokyo University
Tatsuo Kanda, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Nihon University School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Humanity & Health Medical Group Limited
Hong Kong, , Hong Kong
Nihon University School of Medicine
Tokyo, , Japan
Tokyo University
Tokyo, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APCOVLI-2022-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.